VDR rs11568817: Understanding the Cdx2 Promoter Variant
The rs11568817 variant is a single nucleotide polymorphism located in the promoter region of the VDR gene, which encodes the vitamin D receptor. This specific site, often referred to as the Cdx2 binding site, has been investigated for its potential influence on how the body regulates calcium and maintains bone mineral density.
What each genotype means
Typical VDR promoter activity
This genotype represents the common variant in the VDR gene promoter region. Research into this site, often referred to as the Cdx2 polymorphism, has produced mixed results regarding its specific impact on bone mineral density and calcium absorption. Current large-scale studies suggest that any individual effect on fracture risk or bone health is likely very small, and this variant should not be used to predict clinical outcomes.
Carried by a significant portion of the population, with the A-allele frequency typically ranging between 0.15 and 0.20 in European cohorts.
Typical VDR promoter activity
This genotype represents a heterozygous state for the VDR promoter variant. While some early studies investigated whether this site influences how the body regulates bone mineral density, large-scale prospective research has found no significant clinical difference in bone health or fracture risk associated with this genotype. It is considered a common genetic variation with limited impact on overall health.
This is a common heterozygous genotype found across many global populations, consistent with the observed minor allele frequency of approximately 15-20%.
Typical VDR promoter activity
This genotype represents the alternative homozygous state for the VDR promoter variant. While this site is located in a regulatory region of the vitamin D receptor gene, large-scale association studies have generally failed to demonstrate a meaningful clinical impact on bone mineral density or fracture risk. It is considered a common variation that does not require specific medical intervention or monitoring.
This genotype is observed frequently in the general population, reflecting the expected distribution of the Cdx2 promoter variant.
What is the rs11568817 Variant?
The rs11568817 variant is a genetic change located within the promoter region of the VDR gene. In genetics, a promoter is a region of DNA that initiates the transcription of a particular gene. This specific variant is frequently referred to in scientific literature as the Cdx2 polymorphism because it sits within a binding site for the Cdx2 transcription factor. By altering this regulatory sequence, the variant may theoretically influence how much vitamin D receptor protein is produced in various tissues. Because the VDR gene is essential for the body's response to vitamin D, researchers have long hypothesized that variations in this promoter region could lead to subtle differences in how individuals process calcium and maintain their skeletal structure. It is one of several well-studied markers within the VDR locus, alongside others like FokI, BsmI, and TaqI.
The Role of the VDR Gene
The VDR gene provides the instructions for creating the vitamin D receptor, a protein that acts as a transcription factor. When vitamin D binds to this receptor, the complex enters the cell nucleus and regulates the expression of numerous genes involved in calcium and phosphate homeostasis. This process is critical for the development and maintenance of strong bones and teeth. Because vitamin D is a key regulator of bone metabolism, the VDR gene has been a primary candidate for research into the genetic basis of osteoporosis and other bone-related conditions. By controlling the absorption of calcium in the intestines and the activity of bone-remodeling cells, the vitamin D receptor serves as a central hub for skeletal health. Understanding how genetic variants like rs11568817 might modulate this receptor's activity remains a significant area of interest in nutritional and skeletal genomics.
Research Associations and Evidence Strength
Research into rs11568817 has produced mixed results, and the evidence linking it to clinical outcomes is considered limited. Some studies have suggested that specific genotypes at this site may be associated with variations in bone mineral density or the risk of vertebral fractures. For instance, meta-analyses have occasionally identified potential links between the variant and lumbar spine bone density in certain populations. However, other studies have failed to replicate these findings, finding no significant difference in bone turnover markers or bone mass between different genotype groups. These conflicting results highlight the complexity of bone health, which is influenced by a combination of genetics, diet, physical activity, and environmental factors. Because the effect sizes of individual SNPs like rs11568817 are typically very small, they are rarely predictive of health outcomes on their own, and the scientific community remains cautious about drawing definitive clinical conclusions.
Population Frequency
The rs11568817 variant is relatively common, with a minor allele frequency typically reported between 0.15 and 0.20 in European populations. This means that a significant portion of the population carries at least one copy of the variant allele. Because frequencies can vary significantly across different ancestral groups, researchers often emphasize the importance of considering population-specific data when interpreting genetic studies. The prevalence of the different genotypes—homozygous for the major allele, heterozygous, and homozygous for the minor allele—follows standard patterns for a common polymorphism, ensuring that all three genotype combinations are present in most large, diverse cohorts.
Interpreting Your Genetic Information
It is important to understand that having a particular genotype for rs11568817 does not constitute a medical diagnosis or a guarantee of future health. Genetic variants in the VDR gene are just one of many factors that contribute to bone health. Factors such as adequate dietary calcium intake, vitamin D levels, regular weight-bearing exercise, and overall lifestyle choices play a much larger role in maintaining bone density than any single SNP. If you are concerned about your bone health or your vitamin D status, you should consult with a healthcare professional. They can order appropriate blood tests to check your vitamin D levels and assess your bone density through clinical screening. Never use genetic information to make decisions about supplementation or medication without first discussing your specific health needs with a doctor or a registered pharmacist.
How common is this variant?
The minor allele frequency for rs11568817 is approximately 0.15-0.20 in European populations, making the variant relatively common.
Frequently asked questions
Does the rs11568817 variant cause osteoporosis?
No, this variant does not cause osteoporosis. While some research has explored potential associations between this SNP and bone mineral density, it is not a diagnostic marker for the condition.
Should I take more vitamin D if I have the A allele?
You should not change your supplement regimen based on this genetic variant. Always discuss your vitamin D levels and supplementation needs with your healthcare provider, who can evaluate your blood levels and overall health.
Is this variant the same as the FokI or BsmI polymorphisms?
No, rs11568817 is a distinct variant located in the promoter region of the VDR gene. FokI and BsmI are different variants located in other parts of the same gene.
Where can I find more information about VDR gene variants?
You can find reliable information on the VDR gene through resources like MedlinePlus Genetics or the NCBI Gene database. These sites provide comprehensive summaries of gene function and known associations.
Sources & further reading
Educational information only, last refreshed 10/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11568817?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VDR
This variant in the Vitamin D receptor gene is associated with susceptibility to Type 1 Diabetes and autoimmune thyroid disease.
Promoter polymorphism (Cdx2) in the VDR gene associated with bone mineral density and vitamin D metabolism.
Common polymorphism (TaqI variant) in the vitamin D receptor affecting mRNA stability and bone mineral density.
Known as the TaqI polymorphism, this variant is located in the 3' UTR of the VDR gene and is associated with altered mRNA stability, influencing vitamin D signaling, cancer cachexia susceptibility, and gastric cancer risk.
Variant in the VDR promoter (Cdx-2 binding site) associated with bone mineral density and calcium absorption efficiency.
The Cdx2 polymorphism in the VDR promoter influences vitamin D receptor expression and is associated with bone mineral density.